Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,otherLiab,changeToLiabilities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,totalCashFromFinancingActivities,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,marketState,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,GALT,21943000.0,57156000,6371000,,-7852000,,-7852000,1461000,0,-7832000,-7832000,,-22000,,,,0,0,7832000,0,-20000,,-7852000,-7917000,261883000.0,5407000.0,21943000.0,65000.0,29600000.0,56000.0,6000.0,-239996000.0,87000.0,27142000.0,5399000.0,48000.0,29465000.0,1292000.0,,2835000.0,-996000.0,-5414000.0,-5414000.0,9000.0,590000.0,,,24066000.0,en-US,US,EQUITY,True,Delayed Quote,3.9,1630526402,-0.029999971,3.96,4.04,3.88,404966,0.7775364,0.24901375,222908400,-5.652174,10.15625,15,America/New_York,EDT,-14400000,False,False,USD,4,Galectin Therapeutics Inc.,NCM,-0.6,-6.5,0.384,3.151389,0.7486112,0.23754962,3.1224637,0,finmb_1065415,NasdaqCM,Galectin Therapeutics Inc.,USD,2244720,412466,2.08,1.1428571,1.82 - 5.7,-1.7999997,-0.31578943,1.82,5.7,1617177600,1636378200,1636723800,-0.414,-0.69,POST,-0.7615395,1630530801,3.8703,-0.02970004,-0.76335806,3.88 - 4.04,3.93,3.89,4.03,9,40,us_market,2.01,,,5.7,1.82,3.1514,3.1225,2.24M,412.47k,57.16M,,41.31M,29.14%,17.81%,4.86M,1.21,21.54%,8.51%,4.66M,,,,,,0.00%,,,1:6,"Mar 22, 2012","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-37.54%,-67.25%,,,,,,-23.6M,-0.4140,,27.14M,0.47,52k,0.22,5.46,0.38,-20.6M,-11.89M,Value,30071,Healthcare,6,8,2,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",Norcross,678 620 3186,GA,2,1577750400,1619740800,10,United States,http://galectintherapeutics.com,86400,7,4960 Peachtree Industrial Boulevard,Biotechnology,Suite 240
t-1,GALT,29292000.0,57156000,4780000,,-5943000,,-5943000,1146000,0,-5926000,-5926000,,-22000,,,,0,0,5926000,0,-17000,,-5943000,-5955000,261316000.0,2507000.0,29292000.0,,34049000.0,56000.0,,-232080000.0,109000.0,32556000.0,2488000.0,57000.0,33883000.0,691000.0,,-1733000.0,-975000.0,-8212000.0,-8212000.0,10000.0,429000.0,,,31395000.0,en-US,US,EQUITY,True,Delayed Quote,3.9,1630526402,-0.029999971,3.96,4.04,3.88,404966,0.7775364,0.24901375,222908400,-5.652174,10.15625,15,America/New_York,EDT,-14400000,False,False,USD,4,Galectin Therapeutics Inc.,NCM,-0.6,-6.5,0.384,3.151389,0.7486112,0.23754962,3.1224637,0,finmb_1065415,NasdaqCM,Galectin Therapeutics Inc.,USD,2244720,412466,2.08,1.1428571,1.82 - 5.7,-1.7999997,-0.31578943,1.82,5.7,1617177600,1636378200,1636723800,-0.414,-0.69,POST,-0.7615395,1630530801,3.8703,-0.02970004,-0.76335806,3.88 - 4.04,3.93,3.89,4.03,9,40,us_market,2.01,,,5.7,1.82,3.1514,3.1225,2.24M,412.47k,57.16M,,41.31M,29.14%,17.81%,4.86M,1.21,21.54%,8.51%,4.66M,,,,,,0.00%,,,1:6,"Mar 22, 2012","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-37.54%,-67.25%,,,,,,-23.6M,-0.4140,,27.14M,0.47,52k,0.22,5.46,0.38,-20.6M,-11.89M,Value,30071,Healthcare,6,8,2,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",Norcross,678 620 3186,GA,2,1577750400,1619740800,10,United States,http://galectintherapeutics.com,86400,7,4960 Peachtree Industrial Boulevard,Biotechnology,Suite 240
t-2,GALT,34751000.0,57156000,4681000,,-6114000,,-6114000,1421000,0,-6102000,-6102000,,-21000,,,,0,0,6102000,0,-12000,,-6114000,-6180000,260820000.0,4306000.0,34751000.0,66000.0,41317000.0,56000.0,,-226125000.0,131000.0,40768000.0,4275000.0,66000.0,41120000.0,206000.0,,2883000.0,204000.0,-2560000.0,-2604000.0,8000.0,415000.0,44000.0,44000.0,36845000.0,en-US,US,EQUITY,True,Delayed Quote,3.9,1630526402,-0.029999971,3.96,4.04,3.88,404966,0.7775364,0.24901375,222908400,-5.652174,10.15625,15,America/New_York,EDT,-14400000,False,False,USD,4,Galectin Therapeutics Inc.,NCM,-0.6,-6.5,0.384,3.151389,0.7486112,0.23754962,3.1224637,0,finmb_1065415,NasdaqCM,Galectin Therapeutics Inc.,USD,2244720,412466,2.08,1.1428571,1.82 - 5.7,-1.7999997,-0.31578943,1.82,5.7,1617177600,1636378200,1636723800,-0.414,-0.69,POST,-0.7615395,1630530801,3.8703,-0.02970004,-0.76335806,3.88 - 4.04,3.93,3.89,4.03,9,40,us_market,2.01,,,5.7,1.82,3.1514,3.1225,2.24M,412.47k,57.16M,,41.31M,29.14%,17.81%,4.86M,1.21,21.54%,8.51%,4.66M,,,,,,0.00%,,,1:6,"Mar 22, 2012","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-37.54%,-67.25%,,,,,,-23.6M,-0.4140,,27.14M,0.47,52k,0.22,5.46,0.38,-20.6M,-11.89M,Value,30071,Healthcare,6,8,2,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",Norcross,678 620 3186,GA,2,1577750400,1619740800,10,United States,http://galectintherapeutics.com,86400,7,4960 Peachtree Industrial Boulevard,Biotechnology,Suite 240
t-3,GALT,40493000.0,57156000,2144000,,-3556000,,-3556000,1440000,0,-3584000,-3584000,,-22000,,,,0,0,3584000,0,28000,,-3556000,-3550000,260382000.0,1358000.0,40493000.0,,44111000.0,56000.0,,-219945000.0,152000.0,43328000.0,1316000.0,75000.0,43884000.0,660000.0,1000.0,-1449000.0,173000.0,-4152000.0,-4371000.0,9000.0,452000.0,219000.0,219000.0,42568000.0,en-US,US,EQUITY,True,Delayed Quote,3.9,1630526402,-0.029999971,3.96,4.04,3.88,404966,0.7775364,0.24901375,222908400,-5.652174,10.15625,15,America/New_York,EDT,-14400000,False,False,USD,4,Galectin Therapeutics Inc.,NCM,-0.6,-6.5,0.384,3.151389,0.7486112,0.23754962,3.1224637,0,finmb_1065415,NasdaqCM,Galectin Therapeutics Inc.,USD,2244720,412466,2.08,1.1428571,1.82 - 5.7,-1.7999997,-0.31578943,1.82,5.7,1617177600,1636378200,1636723800,-0.414,-0.69,POST,-0.7615395,1630530801,3.8703,-0.02970004,-0.76335806,3.88 - 4.04,3.93,3.89,4.03,9,40,us_market,2.01,,,5.7,1.82,3.1514,3.1225,2.24M,412.47k,57.16M,,41.31M,29.14%,17.81%,4.86M,1.21,21.54%,8.51%,4.66M,,,,,,0.00%,,,1:6,"Mar 22, 2012","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-37.54%,-67.25%,,,,,,-23.6M,-0.4140,,27.14M,0.47,52k,0.22,5.46,0.38,-20.6M,-11.89M,Value,30071,Healthcare,6,8,2,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",Norcross,678 620 3186,GA,2,1577750400,1619740800,10,United States,http://galectintherapeutics.com,86400,7,4960 Peachtree Industrial Boulevard,Biotechnology,Suite 240
